Back to Search
Start Over
A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.
- Source :
-
Acta biochimica et biophysica Sinica [Acta Biochim Biophys Sin (Shanghai)] 2021 Dec 08; Vol. 53 (12), pp. 1625-1639. - Publication Year :
- 2021
-
Abstract
- Mucin 1 (MUC1) has been regarded as an ideal target for cancer treatment, since it is overexpressed in a variety of different cancers including the majority of breast cancer. However, there are still no approved monoclonal antibody drugs targeting MUC1. In this study, we generated a humanized MUC1 (HzMUC1) antibody from our previously developed MUC1 mouse monoclonal antibody that only recognizes MUC1 on the surface of tumor cells. Furthermore, an antibody-drug conjugate (ADC) was generated by conjugating HzMUC1 with monomethyl auristatin (MMAE), and the efficacy of HzMUC1-MMAE on the MUC1-positive HER2+ breast cancer in vitro and in 'Xenograft' model was tested. Results from western blot analysis and immunoprecipitation revealed that the HzMUC1 antibody did not recognize cell-free MUC1-N in sera from breast cancer patients. Confocal microscopy analysis showed that HzMUC1 antibody bound to MUC1 on the surface of breast cancer cells. Results from mapping experiments suggested that HzMUC1 may recognize an epitope present in the interaction region between MUC1-N and MUC1-C. Results from colony formation assay and flow cytometry demonstrated that HzMUC1-MMAE significantly inhibited cell growth by inducing G2/M cell cycle arrest and apoptosis in trastuzumab-resistant HER2-positive breast cancer cells. Meanwhile, HzMUC1-MMAE significantly reduced the growth of HCC1954 xenograft tumors by inhibiting cell proliferation and enhancing cell death. In conclusion, our results indicate that HzMUC1-ADC is a novel therapeutic drug that can overcome trastuzumab resistance of breast cancer. HzMUC1-ADC should also be an effective therapeutic drug for the treatment of different MUC1-positive cancers in clinic.<br /> (© The Author(s) 2021. Published by Oxford University Press on behalf of the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Subjects :
- Animals
Antibodies, Monoclonal, Humanized metabolism
Antibodies, Monoclonal, Humanized therapeutic use
Antineoplastic Agents, Immunological metabolism
Antineoplastic Agents, Immunological therapeutic use
Apoptosis drug effects
Breast Neoplasms blood
Breast Neoplasms pathology
Cell Cycle Checkpoints drug effects
Cell Line, Tumor
Cell Proliferation drug effects
Drug Resistance, Neoplasm immunology
Epitopes
Humans
Immunoconjugates therapeutic use
Mice
Mice, Inbred BALB C
Mice, Nude
Mucin-1 blood
Mucin-1 chemistry
Mucin-1 immunology
Oligopeptides chemistry
Oligopeptides pharmacology
Oligopeptides therapeutic use
Receptor, ErbB-2 immunology
Receptor, ErbB-2 metabolism
Xenograft Model Antitumor Assays
Antibodies, Monoclonal, Humanized pharmacology
Antineoplastic Agents, Immunological pharmacology
Breast Neoplasms drug therapy
Drug Resistance, Neoplasm drug effects
Immunoconjugates pharmacology
Mucin-1 metabolism
Trastuzumab pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1745-7270
- Volume :
- 53
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Acta biochimica et biophysica Sinica
- Publication Type :
- Academic Journal
- Accession number :
- 34586349
- Full Text :
- https://doi.org/10.1093/abbs/gmab141